When considered in relation to clinical outcome, MCT1 expression was linked to worse PFS and OS in oropharyngeal cancer, which represents the largest subgroup in our cohort, at p = 0.008 and 0.001, respectively. This evidence concerns the gene SLC16A1 and oropharynx cancer.